Global Blood Plasma Market Trends, Share, Size & Analysis 2018-2026

Blood Plasma Market Forecast 2018-2026.

• The Global Blood Plasma market is driven by factors like growing patient pool for hemophilia, the high prevalence of alpha-1 antitrypsin deficiency and the advent of new therapeutic indications. • By the end of the forecast period of 20182026, the market is slated to account for a CAGR of 6.62%.

•

The global blood plasma market is segmented according to the blood type, applications and end-users.

•

The blood type segment includes Intravenous immunoglobulin, Immunoglobulin, Subcutaneous immunoglobulin, and other immunoglobulin type along with Hyperimmune, Albumin, Coagulation factor concentrates and other plasma fractionation products.

•

Blood plasma finds its application in oncology, immunology, pulmonology, transplantation, rheumatology, neurology, haematology and other applications.

•

The end-users for this market are academic institutions, research

“Global Blood Plasma Market is forecasted to expand further with a CAGR growth of 6.62% during the forecast years of 2018-2026.�

Increasing number of people suffering from chronic diseases and the rising prevalence of blood cancers can be majorly attributed to the North American blood plasma market’s growth. Between the projected years of 2018-2026, the North American blood plasma market is expected to progress with a CAGR of 6.77%.

The Asia-Pacific region is expected to rise with the fastest CAGR of 6.87% for the forecast period of 20182026. The market’s enhanced potential for growth in the past few years has encouraged several companies to invest in this region.

Europe blood plasma market is likely to expand over the forecast period of 2018-2026, by exhibiting a CAGR of 6.58%.

Leading companies such as Adma Biologics Inc, Arthrex, Baxter International Inc, Biotest Ag, Cerus Corp, China Biologic Products Inc, Csl Ltd, General Electric Co, Grifols International S.A, Octopharma Ag, and Shire Plc are actively engaged in this market.